The Stage I single ascending dosage dual blind placebo managed randomized study will involve 48 healthy male volunteers who will receive the drug in six escalating dosage cohorts. Later in 2004, the SAD study will be followed by a multiple ascending dose Phase I research . If Phase I development is successful, Peptimmune anticipates launching a Stage II trial in individuals with obesity in 2005. Related StoriesResearchers discover rise in state-level obesity-related healthcare costsAustralian researchers define essential characteristics of metabolically healthful obeseStanding one-quarter of your day linked to reduced likelihood of obesityGT389-255 can be a novel conjugate of a pancreatic lipase inhibitor and a excess fat binding hydrogel polymer.We are excited to increase our set of small enterprise plans with OBT. In huge component, our decision to partner with OBT was powered by our curiosity in novel therapeutic antibody targets recognized through the OGAP proteomic data source, said Yasunori Yamaguchi, CEO and President of BioWa.. Atenolol beta-blocker might not be effective in reducing center attacks A report published in this weeks problem of THE LANCET claim that atenolol – probably the most widely prescribed beta-blockers for lowering blood circulation pressure – might not be effective in reducing center attacks or loss of life from cardiovascular causes. Atenolol is among the mostly used beta-blockers clinically, and has frequently been utilized as a reference medication in randomised managed trials of high blood circulation pressure.

Other entries from category "laboratory":

Random entries